Inventor · disambiguated record

Anna Borodovsky

Also filed as: BORODOVSKY ANNA

20 granted patents·35 pending applications·86 citations·filing 2003–2024

94Inventor score

Technology areasC12N A61P A61K G01N C12Y

Files withALNYLAM PHARMACEUTICALS INC42 DE FOUGEROLLES ANTONIN4 ARBUTUS BIOPHARMA CORP3 AKING AKIN1 CIUFOLINI MARCO A1

Top patents by PatentIndex Score

55 records

0198US9249415B2Complement component C5 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Feb 2, 2016·24 cites·30 claims
0296US11873491B2Complement component C5 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Jan 16, 2024·2 cites·32 claims
0396US9850488B2Complement component C5 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Dec 26, 2017·11 cites·62 claims
0496US9701963B2Complement component C5 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2016·Granted Jul 11, 2017·9 cites·32 claims
0594US11326166B1Xanthine dehydrogenase (XDH) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted May 10, 2022·3 cites·29 claims
0693US11186842B2Complement component iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Nov 30, 2021·4 cites·18 claims
0793US10465194B2Complement component iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2016·Granted Nov 5, 2019·11 cites·11 claims
0890US11162098B2Complement component C5 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Nov 2, 2021·2 cites·19 claims
0987US10125369B2PCSK9 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2013·Granted Nov 13, 2018·9 cites·85 claims
1087US7759320B2Compositions and methods for inhibiting expression of a gene from the EbolaALNYLAM PHARMACEUTICALS INC·Filed 2008·Granted Jul 20, 2010·6 cites·21 claims
1187US2024376477A1COMPLEMENT COMPONENT iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
1286US11866701B2Complement component C3 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2018·Granted Jan 9, 2024·2 cites·24 claims
1381US2024175017A1Complement component c5 irna compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
1481US2023390321A1COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
1578US2024294912A1COMPLEMENT COMPONENT C3 iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
1678US2025197855A1COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USEALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
1777US2022213486A1COMPLEMENT COMPONENT iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
1877US2022074925A1Screening method for selected amino-lipid-containing compositionsARBUTUS BIOPHARMA CORP·Filed 2021·Application pending·0 cites
1975US2011097720A1Screening method for selected amino lipid-containing compositionsALNYLAM PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
2074US12460206B2PCSK9 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Nov 4, 2025·0 cites·2 claims
2174US8735369B2Compositions and methods for inhibiting expression of a gene from the Ebola virusALNYLAM PHARMACEUTICALS INC·Filed 2012·Granted May 27, 2014·1 cites·17 claims
2274US8288525B2Compositions and methods for inhibiting expression of CD45 geneDE FOUGEROLLES ANTONIN·Filed 2009·Granted Oct 16, 2012·1 cites·14 claims
2374US2020225215A1Screening method for selected amino-lipid-containing compositionsARBUTUS BIOPHARMA CORP·Filed 2019·Application pending·0 cites
2473US2020069723A1COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
2573US2020339998A1COMPLEMENT COMPONENT iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
2671US2021177884A1COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
2769US9029338B2Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virusDE FOUGEROLLES ANTONIN·Filed 2010·Granted May 12, 2015·1 cites·16 claims
2869US2022403381A1Complement component c5 irna compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
2969US2020032258A1Complement component c5 irna compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
3068US2017268005A1COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
3168US2018169132A1COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
3268US2018209963A1Screening method for selected amino-lipid-containing compositionsARBUTUS BIOPHARMA CORP·Filed 2017·Application pending·0 cites
3367US2022411801A1XANTHINE DEHYDROGENASE (XDH) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
3466US9187516B2Compositions and methods for inhibiting expression of a gene from the Ebola virusALNYLAM PHARMACEUTICALS INC·Filed 2014·Granted Nov 17, 2015·0 cites·17 claims
3566US2024360454A1Renal injury biomarkers as biomarkers for acute hepatic porphyria (ahp)ALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
3665US2021395735A1COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USEALNYLAM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
3764US2014295449A1Screening method for selected amino lipid-containing compositionsTEKMIRA PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
3864US2024132886A1COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
3963US2023136552A1COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)ALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
4063US2012225434A1Screening method for selected amino lipid-containing compositionsCIUFOLINI MARCO A·Filed 2012·Application pending·0 cites
4163US2016274089A1Screening method for selected amino-lipid-containing compositionsTEKMIRA PHARMACEUTICALS CORP·Filed 2015·Application pending·0 cites
4262US2017253874A1Complement component c5 irna compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
4360US8354390B2Compositions and methods for inhibiting expression of a gene from the ebola virusALNYLAM PHARMACEUTICALS INC·Filed 2011·Granted Jan 15, 2013·0 cites·17 claims
4459US2015093417A1Compositions And Methods For Inhibiting Expression Of CD45 GeneALNYLAM PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
4558US8912316B2Compositions and methods for inhibiting expression of CD45 geneDE FOUGEROLLES ANTONIN·Filed 2012·Granted Dec 16, 2014·0 cites·23 claims
4658US7973020B2Compositions and methods for inhibiting expression of a gene from the ebola virusALNYLAM PHARMACEUTICALS INC·Filed 2010·Granted Jul 5, 2011·0 cites·9 claims
4757US2023125933A1Mannan binding lectin serine peptidase 2 (masp2) irna compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
4857US2016264972A1Compositions and Methods for Inhibiting Expression of a Gene from the Ebola VirusALNYLAM PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
4955US2025283071A1Modified double stranded oligonucleotidesALNYLAM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
5055US2011218334A1PHOSPHOROTHIOATE OLIGONUCLEOTIDES AND NON-NUCLEOSIDIC PHOSPHOROTHIOATES AS DELIVERY AGENTS FOR iRNA AGENTSALNYLAM PHARMACEUTICALS INC·Filed 2009·Application pending·0 cites

Showing the top 50 of 55 patent records by PatentIndex Score.

Join the waitlist — get patent alerts

Get an alert when Anna Borodovsky files or is granted a new patent.

We store only your email — no account needed. See our privacy policy.

Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →